Abstract
Esophageal squamous cell carcinoma (ESCC) is strongly characterized by a male predominance with higher mortality rates and worse responses to treatment in males versus females. Despite the role of sex hormones, other causes that may contribute to sex bias in ESCC remain largely unknown, especially as age increases and the hormone difference begins to diminish between sexes. In this study, we analyzed genomics, transcriptomics, and epigenomics from 663 ESCC patients and found that G2/M checkpoint pathway-related sex bias and age bias were significantly present in multi-omics data. In accordance with gene expression patterns across sexes, ten compounds were identified by applying drug repurposing from three drug sensitivity databases: The Connective Map (CMap), Genomics of Drug Sensitivity in Cancer (GDSC), and The Cancer Therapeutic Response Portal (CTRP). MK1775 and decitabine showed better efficacy in two male ESCC cell lines in vitro and in vivo. The drugs’ relevance to the transition between G2 and M was especially evident in male cell lines. In our study, we first validated the sex bias of the G2/M checkpoint pathway in ESCC and then determined that G2/M targets may be included in combination therapy for male patients to improve the efficacy of ESCC treatment.
Funder
the National Key R&D Program of China
the National Natural Science Foundation of China
the CAMS Innovation Fund for Medical Sciences
Reference63 articles.
1. Sex disparities matter in cancer development and therapy;Haupt;Nat. Rev. Cancer,2021
2. Sex disparities in cancer mortality and survival;Cook;Cancer Epidemiol. Biomark. Prev.,2011
3. Sex differences in lung cancer survival: Do tumors behave differently in elderly women?;Wisnivesky;J. Clin. Oncol.,2007
4. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials;Wheatley-Price;J. Thorac. Oncol.,2010
5. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data;Yang;Sci. Transl. Med.,2019